Printer Friendly

ANS Unveils Rapid Programmer 3.0 at American Academy of Pain Medicine Conference; New Compact Neurostimulation Programming Platform Provides Easy-to-Use Interface, Enhanced Graphics, and Significant Programming Advances.

PLANO, Texas -- Advanced Neuromodulation Systems (ANS), the Neuromodulation business of St. Jude Medical, Inc. (NYSE:STJ), today announced its newest programming platform, Rapid Programmer(R) 3.0, for the management of spinal cord stimulation, a therapy used for treating chronic pain of the trunk and limbs. Introduced at the 22nd American Academy of Pain Medicine (AAPM) annual meeting in San Diego, California, this platform delivers advanced programming features, including Dynamic MultiStim(TM) and Active Balancing(TM) programming, both of which are industry firsts.

Rapid Programmer 3.0 is the smallest and lightest-weight (6.49 ounce) clinician programmer in the industry. This powerful handheld system features enhanced graphics and an intuitive Windows(R)-based graphical user interface. It is also available as a software upgrade to the ANS Rapid Programmer(R) platform, first introduced to the market in September 2003, and is fully-compatible with the full family of ANS spinal cord stimulation products, including the Eon(TM), Genesis(R), GenesisXP(TM), GenesisRC(TM), and Renew(R) neurostimulation systems, as well as the MTS(R) trial stimulator.

"The new Rapid Programmer 3.0 empowers clinicians to deliver more efficient and effective patient care and is designed to decrease the average postoperative programming time," said Chris Chavez, president of Advanced Neuromodulation Systems. "For the first time, clinicians have the ability to test and make real-time changes to multiple areas of stimulation coverage."

Key features of Rapid Programmer 3.0 include:

--Dynamic MultiStim - This advanced electrical field management technology allows for precise real-time optimization of multiple areas of stimulation coverage.

--Active Balancing - This capability enables the clinician to fine tune the amplitude levels of various stimulation coverage areas simultaneously, easily establishing a comfortable level for the patient.

--Calibrated Testing - This automated feature allows the clinician to map the neurostimulation system's interaction with the patient's nervous system and quickly move through programming scenarios.

--Patient Database - Rapid Programmer 3.0 contains an easily-accessible, large-capacity database that securely stores patient records on a single programmable card. Vital patient information, such as stimulation parameters for trial and permanent implants, can be captured during programming and stored in one paper-free location. Information can also be exported for use with other programs.

About Advanced Neuromodulation Systems (ANS)

ANS ( is an innovative technology leader dedicated to the design, development, manufacturing and marketing of implantable neuromodulation systems to improve the quality of life for people suffering from disabling chronic pain and other nervous system disorders. Headquartered in Plano, Texas, ANS is a division of St. Jude Medical (

About St. Jude Medical

St. Jude Medical is dedicated to making life better for cardiac, neurological and chronic pain patients worldwide through excellence in medical device technology and services. The company has five major focus areas that include: cardiac rhythm management, atrial fibrillation, cardiac surgery, cardiology, and neuromodulation. Headquartered in St. Paul, Minnesota, the company employs approximately 10,000 people worldwide. For more information, please visit

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such forward-looking statements include the expectations, plans and prospects for the Company, including anticipated future product launches, regulatory approvals, revenues, earnings, market shares, and potential clinical success. The statements made by the Company are based upon management's current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include market conditions and other factors beyond the Company's control and the risk factors and other cautionary statements described in the Company's filings with the SEC, including the Cautionary Statements section in Item 2 of the Company's Quarterly Report on Form 10-Q filed on November 8, 2005 (see page 35). The Company does not intend to update these statements and undertakes no duty to any person to provide any such update under any circumstance.
COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Feb 27, 2006
Previous Article:Applied's New HiPOx Plus System Meets Utilities' Critical Need for Destroying Taste and Odor Contaminants in Drinking Water.
Next Article:Nero Announces U.S. Retail Release of Nero PhotoShow Deluxe 4; Easy-to-Use Software Lets Users Manage Digital Photo Collection and Post PhotoShows on...

Related Articles
Advanced Neuromodulation Systems Comments on Boston Scientific's Acquisition of Advanced Bionics.
Advanced Neuromodulation Systems Announces FDA Approval of First Generation Rechargeable Neurostimulation Systems.
Advanced Neuromodulation Systems Completes Sale of All of Its Cyberonics Shares.
PMC-Sierra demonstrates micro Multi-Service Provisioning Platform capabilities with new evaluation system.
Advanced Neuromodulation Systems To Release Second Quarter Results Thursday, July 28, 2005; WebCast Set For 11:00 a.m. EDT.
Medtronic Receives FDA Approval for Non-Rechargeable Neurostimulator; RestorePRIME(TM) Neurostimulation System Offers Unrivaled Convenience, Control...
Advanced Neuromodulation Systems Receives European CE Mark Clearance for Eon Rechargeable Neurostimulation System; First Patient Implant Completed in...
Medtronic Releases "ADVANCED" Neurostimulators for Treatment of Chronic Pain.
Advanced Neuromodulation Systems Receives Australian Regulatory and Reimbursement Approval for Rechargeable Chronic Pain System.
Advanced Neuromodulation Systems Receives European Approval for Rapid Programmer(R) 3.0 Clinician Programming Platform.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters